Sun Pharmaceutical Organon Deal: Global and domestic nrokerages have turned increasingly constructive on Sun Pharmaceutical Industries following its announcement to acquire Organon & Co., citing the deal's strategic fit, earnings accretion and strong cash-flow profile.

Several analysts have raised their target prices on the stock and now peg upside of up to 16 per cent from current levels, highlighting portfolio diversification into women's health and biosimilars, cost and revenue synergies, and long-term improvement in scale and profitability.

Notably, shares of Sun Pharmaceutical Industries surged more than 9 per cent on Monday, extending their strong recent run after the acquisition. The rally pushed the stock to within touching distance of its all-time high of Rs 1,851.20, hit on May 2, leaving it just about 4 per cent below peak levels.

Brokerages On Sun Pharma

Motilal Oswal On Sun Pharma

• The brokerage maintains 'Buy' with target price of Rs 2,025
• Sun pharma organon acquisition will provide several advantages for SUNP in terms of portfolio expansion, healthcare professional connect, & geographical reach
• Transaction strengthens global positioning with attractive valuation and strategic fit
• Notably, Organon's stable EBITDA margins & annual free cash flow of USD 1 billion should boost SUNP's overall financials.
• Expect co to see a meaningful scale-up after the Organon acquisition, with pro forma revenue of USD 12.4 billion and EBITDA of USD 3.7 billion, supported by the addition of a stable, margin-resilient business with strong cash flow characteristics.

Morgan Stanley on Sun Pharma

• Acquisition of Organon at EV of USD 11.75bn to create global pharma platform
• Diversifies beyond India/US generics into women's health and biosimilars
• Revenue synergies via cross-selling and in-licensing key upside driver
• Cost synergies of USD 350mn over 2-4 years
• Net debt rises to 2.3 times Ebitda post deal
• Strong FCF of USD 2.5-3bn enables deleveraging in 3 years
• EPS accretive from Year 1
• Deal expected to close by early 2027

Nuvama On Sun Pharmaceuticals

• The brokerage maintains 'Buy' with a revised target price of Rs 2,000 versus Rs 1,875
• SUNP to acquire 100 per cent stake in Organon, deal to close early 2027
• Positive on Organon deal as it accelerates SUNP's shift toward innovative/high-value drugs post integration.
• Leveraging Organon's Women's health segment; enters biosimilars
• SUNP gains a diversified portfolio and a scaled global platform across women's health, biosimilars and established brands
• This transaction strengthens Sun's global scale, portfolio diversification and cross-selling potential.
• EPS accretive acquisition with steady synergy upside
• EPS accretion estimate of 30-40 per cent for FY28E.
• At 1.9 times EV/sales and 6.2 times EV/EBITDA (FY27E) valuations remain attractive, with further improvement expected as synergies flow through.